secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001297184-23-000063
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q2 2023 revenue $145.7M, GAAP EPS $0.49, adj. EPS $0.65
-----------------------------------------------------------------

- Net revenues $145.7M for Q2 2023, up 18% from $123.5M in Q2 2022.
- GAAP net income $26.1M ($0.49 diluted EPS) vs $17.3M ($0.33) YoY.
- Adjusted non-GAAP net income $34.8M ($0.65 diluted EPS) vs $20.7M ($0.39) YoY.
- Completed BAQSIMI acquisition June 30; glucagon, phytonadione, and newer products drove growth.
- Six-month: revenue $285.7M, GAAP net income $52.2M ($0.99 EPS), adj. net income $66.9M ($1.27 EPS).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718423000063/0001297184-23-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718423000063/amph-20230808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-23-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer